Yes, prednisone can cause both anxiety and depression as recognized neuropsychiatric side effects.
Prednisone and other corticosteroids are well-documented to cause psychiatric disturbances ranging from emotional instability and anxiety to severe depression and psychosis. These effects are explicitly listed in the FDA drug label and multiple clinical guidelines 1.
Mechanism and Prevalence
The neuropsychiatric effects of prednisone occur through disruption of the hypothalamic-pituitary-adrenal (HPA) axis and direct effects on brain neurotransmitter systems. According to the FDA label, psychiatric derangements may range from euphoria, insomnia, mood swings, and personality changes to severe depression and frank psychotic manifestations 1. Existing emotional instability or psychotic tendencies may be aggravated by corticosteroids 1.
Research demonstrates that severe neuropsychiatric consequences (including depression, panic disorder, mania, and psychosis) occur in 15.7 per 100 person-years at risk for all glucocorticoid courses, and 22.2 per 100 person-years for first courses 2. The majority of patients experience less severe but distressing changes in mood, cognition, memory, or behavior during treatment or withdrawal 2.
Clinical Presentation
Anxiety Symptoms
- Emotional instability and irritability 1
- Restlessness and insomnia 1
- Panic-like symptoms 2
- Increased motor activity 1
Depressive Symptoms
- Depression (more common during long-term treatment) 3
- Mood swings and personality changes 1
- Withdrawn behavior 1
- Severe depression requiring intervention 2
Notably, while hypomania and mania are most common during acute therapy, depression is reported more frequently during long-term corticosteroid treatment 3.
Risk Factors and Dose Relationship
The psychiatric effects are dose-dependent and frequently occur during the first few weeks of therapy 3. Clinical guidelines specifically list "emotional lability" as a reason to prefer combination therapy with azathioprine over prednisone monotherapy, as the combination regimen uses lower corticosteroid doses 4.
Recent population-based research found that corticosteroid users, particularly those on inhaled and systemic types, showed:
- Higher likelihood of mood disorders (OR 1.40 for inhaled corticosteroids) 5
- Higher likelihood of anxiety disorders (OR 1.19 for inhaled corticosteroids) 5
- Reduced executive cognitive functioning 5
In patients with severe prednisone-dependent asthma, the prevalence of clinically significant depressive symptoms was 9% versus 0% in non-prednisone dependent groups, and anxiety symptoms occurred in 19% versus 5.5-6.4% in comparison groups 6.
Clinical Management Recommendations
Monitoring
Proactive screening and management for quality of life and mental health symptoms is recommended 7, 8. The 2025 EASL guidelines emphasize that up to 70% of patients report low quality of life during corticosteroid therapy, with high doses leading to neuropsychiatric disorders including anxiety, insomnia, depression, and even psychosis 8.
Prevention Strategies
- Use the lowest effective dose: Taper prednisone rapidly once biochemical response is achieved 7
- Combination therapy preferred: Using prednisone with azathioprine allows lower corticosteroid doses (10% versus 44% side effect rate compared to high-dose prednisone monotherapy) 4
- Consider budesonide in appropriate patients: May have reduced neuropsychiatric intensity due to first-pass metabolism 7
- Avoid prolonged high-dose monotherapy: Especially doses >10 mg daily 7
Treatment of Psychiatric Symptoms
Controlled trials suggest that lithium and phenytoin can prevent mood symptoms associated with corticosteroids, while lamotrigine and memantine may reverse declarative memory effects 3. Uncontrolled trials indicate antipsychotics, anti-seizure medications, and some antidepressants can normalize mood changes 3.
The symptoms and treatment response are similar to bipolar disorder, and corticosteroid-induced mood and cognitive alterations are reversible with dose reduction or discontinuation 3.
Important Caveats
- Psychiatric symptoms can occur at any point during therapy, even after treatment has stopped 9
- Signs may be minimal initially but progress to severe manifestations 1
- Patients should be warned about these risks before initiating therapy 1
- Medical supervision is essential when discontinuing corticosteroids to avoid withdrawal syndrome (which itself includes anxiety and depression-like symptoms) 1
The relationship is bidirectional: stress and psychiatric conditions can worsen underlying disease requiring corticosteroids, while corticosteroids themselves induce or exacerbate psychiatric symptoms 10.